Cat. No.: DAA-001083
Product Information | |
---|---|
Product Name | Human EGFL7 Antibody Pair - BSA and Azide free |
Species | Human |
Description | Both capture and detector antibodies are recombinant rabbit monoclonal antibodies delivering consistent, specific, and sensitive results. The Antibody Pair can be used to quantify Human EGFL7. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. |
Detection Range | 0.469 ng/mL - 30 ng/mL |
Target Information | |
---|---|
Target Name | EGFL7 |
UniProt No. | Q9UHF1 |
Gene ID | 51162 |
Target Description | Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cells adhesion to the substrate in vitro. |
Alternative Names | EGF like domain 7; EGF like domain containing protein 7; EGF like domain multiple 7; EGF-like protein 7; EGFL 7; EGFL7; EGFL7_HUMAN; Epidermal growth factor like domain protein 7; Epidermal growth factor-like protein 7; MEGF 7; MEGF7; MGC111117; Multiple EGF like domain protein 7; Multiple EGF-like domains protein 7; Multiple epidermal growth factor like domain protein 7; Multiple epidermal growth factor-like domains protein 7; NEU1; NEU1 protein; NOTCH4 like protein; NOTCH4-like protein; RP11 251M1.2; UNQ187/PRO1449; Vascular endothelial statin; VE statin; VE-statin; ZNEU 1; ZNEU1 |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.